Measles is roaring back in the U.S. with cases hitting 35-year highs, fueled by plummeting vaccination rates below the 95% threshold needed for herd immunity. Scientists are racing to develop treatments—like monoclonal antibodies and antivirals—to protect those who can’t be vaccinated, as measles can cause pneumonia, deafness, and brain damage. While promising therapies are in the pipeline from labs like Invivyd and Vanderbilt, the real challenge is convincing vaccine-hesitant populations to use them. With outbreaks looming and potential deaths on the rise, this urgent research could be the lifeline we need to stop the spread.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
